Additional data on safety.
CEM-101 has completed Stage 2 trials in community-acquired bacterial pneumonia for the oral dosage type and is in Phase 1 for the IV dosage type. Data presented at this year’s ICAAC conference contributes additional data on the protection, tolerability and dosing profile of our 4th generation macrolide, CEM-101, said Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra. Sankaran to receive Rising Star AwardFirst medical center installs Ortho Eyesight AnalyzerCareFusion to display brand-new respiratory solutions at AARC CongressMacrolides are a potent course of antibiotics which have been beneficial for treating respiratory infections.S.Harding. For more information about Huntington’s disease, visit:.. Aethlon seeks FDA conference for re-initiation of Hemopurifier IDE study Aethlon Medical, Inc. announces that it provides submitted a request to the U.S.S.’ The ending up in the FDA provides a collaborative chance of Aethlon administration to interact directly with Agency officials and to obtain assistance and insight on advancing both its HCV and Medical Countermeasure indications in the U.S.4 percent sustained virologic response rates in HCV patients who previously failed HCV-SOC.1 percent. Recent research have clearly shown that HCV-infected ESRD sufferers on maintenance dialysis are in increased risk of liver-related mortality.S.